IONIS PHARMACEUTICALS INC

Drug pipeline (12)

Asset	Stage	Revenue	Trials	Status
DAWNZERA (AUTOINJECTOR)	approved	—	0	—
TRYNGOLZA (AUTOINJECTOR)	approved	—	0	—
ZANVASTRO	approved	—	1	approved
ULEFNERSEN	phase3	—	1	active
COFIRASERSEN	phase2	—	2	completed, terminated

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (109)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00002355	—	completed	—	—	Ionis Pharmaceuticals, Inc.	A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
NCT03647228	phase1	completed	2018-12-13	2020-10-13	Ionis Pharmaceuticals, Inc.	A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
NCT00002156	phase2	completed	—	—	Ionis Pharmaceuticals, Inc.	A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
NCT02312011	phase1_2	completed	2014-12-01	2016-07-01	Ionis Pharmaceuticals, Inc.	A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
NCT02476019	phase2	completed	2015-06-01	2016-07-01	Ionis Pharmaceuticals, Inc.	A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

FDA applications (3)

Application

Approved

Type

Applicant

Products

NDA 219407

2025-08-21

NDA

IONIS PHARMACEUTICALS INC

NDA 218614

2024-12-19

NDA

IONIS PHARMACEUTICALS INC

NDA 220210

—

NDA

IONIS PHARMS INC